Dioscorealide B is a pharmacologically active compound from the rhizome of the Thai medicinal plant Dioscorea membranacea. Here, we demonstrated that in vitro treatment of dioscorealide B resulted in a cytotoxic effect on MCF-7 human breast cancer cells (IC 50 = 2.82 µM). To determine whether this compound induces apoptosis in MCF-7, the Annexin V assay was performed. The data showed that the number of apoptotic cells were increased 7-12 folds over that of the control cells after treatment with various concentrations of dioscorealide B (3, 6 and 12 µM) for 24 hours. Dioscorealide B-induced apoptosis was associated with modulation of the multidomain Bcl-2 family members Bax, Bak and Bcl-2. After treatment with 3 µM dioscorealide B, acceleration of the level of proapoptotic proteins Bax and Bak were observed at 6 hours and 12 hours, respectively, while the decrease in the expression of antiapoptotic protein Bcl-2 was observed 3 hours after the treatment. These effects of dioscorealide B might result in the activation of caspase-8, -9 and -7, which lead to apoptosis in MCF-7 cells. Taken together, the results of this study provide evidence that dioscorealide B possesses an antitumor property against human breast cancer cells and thus provide the molecular basis for the further development of dioscorealide B as a novel chemotherapeutic agent for breast cancer treatment.
Breast cancer is the most common cancer in women worldwide, comprising 16% of all female cancers. It is estimated that 519,000 women died in 2004 due to this disease, and although it is thought to be a problem of the developed world, a majority (69%) of all breast cancer deaths occurs in developing countries [1] . The American Cancer Society estimated that 192,370 new cases of invasive breast cancer would be diagnosed in women in the U.S. and about 40,170 breast cancer deaths were expected in 2009 [2] . These statistics accentuate the immediate need for improvements in detection, diagnosis, and treatment of this disease. Breast cancer is currently controlled through surgery and/or radiotherapy, and is frequently supported by adjuvant chemo-or hormonal therapies. However, these classical treatments are impeded by unwanted side effects and, most importantly, the development of tumor resistance. The medicinal use of naturally occurring substances or natural agents then becomes an alternative for the patients suffering from cancer [3, 4] . preparations, including those used in the treatments of lymphopathy, dermopathy, venereal diseases, leprosy, bacterial infections and cancers [5] [6] [7] . Previous study revealed that dioscorealide B, one of the isolated compounds from D. membranacea, has cytotoxic activity against MCF-7 human breast cancer cells and has been shown to serve as an anti-proliferative and selective cytotoxic agent. The compound selectively inhibited the proliferation of breast cancer cell line (MCF-7), without being significantly cytotoxic towards non-malignant cells (SVK) [8] . In the present study, some mechanisms related to apoptosis, which might underlie the antiproliferation activity of dioscorealide B, have been investigated.
In this study, the cytotoxic effect of dioscorealide B on MCF-7 was determined by SRB assay. Dioscorealide B showed a cytotoxic effect on MCF-7 with an IC 50 value of 2.82 ± 0.36 µM (Figure 2 ), whereas vinblastine, the positive control, had a stronger cytotoxic effect with anIC 50 value of 1.65 ± 0.13 nM. This result confirmed that dioscorealide B was able to inhibit in vitro growth of MCF-7. Cancer is an aberrant net accumulation of atypical cells which can arise from an excess of proliferation, an insufficiency of apoptosis, or a combination of the two [9] . Increased frequency of apoptosis could result in cell loss in tumors and promote tumor regression. In cancer treatment, a major recent focus is on activating the apoptotic program in the cell [10] , and there is evidence that many anticancer agents cause tumor cell death via the mechanisms of apoptosis [11] [12] [13] . Thus, we extended our study to examine whether the anti-tumor property against breast cancer cells is mediated through apoptosis induction after dioscorealide B treatment. MCF-7 cells were stained with Annexin V-FITC and PI, and then subsequently analyzed by flow cytometry. This assay is based on the translocation of phosphatidylserine from the inner leaflet of the plasma membrane to the cell surface in the early apoptotic cells. MCF-7 cells were challenged with dioscorealide B at 3, 6 and 12 µM for 24 h. We found that dioscorealide B significantly induced apoptosis in a dose-dependent manner compared with control cells. The numbers of apoptotic cells in MCF-7 were increased to 7.02, 11.87 and 12.17 fold after 3, 6 and 12 µM dioscorealide B treatment, respectively ( Figure 3B ). Caspases are members of a family of cysteine proteases that play a crucial role in the apoptotic pathway [14, 15] . There are two major mechanisms that initiate the caspase cascade: the extrinsic, involving caspase-8; and the intrinsic pathway, involving caspase-9 as the apical caspase, which leads to the proteolytic activation of effector caspases, including caspase-3 and -7, which cleave the cellular substrate, resulting in cell death [16, 17] . The extrinsic pathway is triggered by the interaction between a death ligand, such as TNF or FasL, and its cognate receptor, TNF-R or Fas (CD95), inducing the trimerization of the receptors, which recruit adaptor proteins such as FADD and procaspase-8, leading to the activation of caspase-8 [18, 19] . The intrinsic pathway is regulated by the Bcl-2 family of proteins, including proapoptotic members such as Bax and Bak, and anti-apoptotic members such as Bcl-2 and Bcl-X L [20] [21] [22] . In response to apoptotic signals, proapoptotic Bcl-2 family members translocate to and alter the permeability of the mitochondrial membrane [23] . These proteins are thought to either form channels in the outer mitochondrial membrane or to alter the activity of existing channels, leading to changes in the mitochondrial membrane potential and cytochrome c release. Cytochrome c then interacts with Apaf-1 and procaspase-9, which in turn activates caspase-9 [24, 25] .
To gain insights into the mechanism of apoptosis induction in MCF-7, the effect of dioscorealide B treatment on levels of Bcl-2 family proteins by western blotting was studied and the results are shown in Figure  4 . Following treatment with 3 µM of dioscorealide B, the formation of anti-apoptotic protein Bcl-2 was downregulated after three hours, whereas the expression of proapoptotic protein Bax was upregulated after six hours. The dioscorealide B treatment also caused an increase in the protein level of Bak, as observed at twelve hours. Next, we examined whether the caspases are involved in dioscorealide B-induced apoptosis. Immunoblot analyses of lysates obtained from MCF-7 cells treated with dioscorealide B at 3 µM were examined and results are shown in Figure 5 . The cleaved form of caspase-7 increased after three hours and procaspase-7 was totally cleaved after twenty-four hours of treatment, suggesting that this compound induces the activation of caspase-7. Dioscorealide B increased the activity of caspase-7 activity in a dose-and time-dependent manner, as demonstrated in Figures 6 and 7 . After incubation with 3 µM of dioscorealide B, the caspase-7 activity significantly increased to 230% at six hours. The effect of dioscorealide B on caspase-8 and caspase-9 activities is shown in Figure 8 . Our findings revealed that activation of caspase-9 significantly increased after treatment of the cells with dioscorealide B, starting from three hours of exposure time, but caspase-8 activity showed a significant elevation after only one hour of treatment. Figure 9 , pretreatment of MCF-7 cells with either the caspase-8 inhibitor or the caspase-9 inhibitor significantly decreased the caspase-7 activity. These results suggested that this bioactive compound might be involved in both intrinsic and extrinsic apoptotic pathways. This observation further supports the fact that induction of apoptosis in MCF-7 cells by dioscorealide B is mediated through reduction of antiapoptotic protein Bcl-2 expression and induction of proapoptotic protein Bax and Bak expression, leading to the activation of caspase-9 and -7, respectively. However, the mechanism of diosocorealide B in the extrinsic pathway needs to be refined. The role of the TNF superfamily such as Fas, Fas ligand, TNF-R1 and TNF-α might be investigated in the further study. In this study, we found that dioscorealide B caused an increase in both caspase-8 and -9 activities. Bid, a BH3 domain-containing proapoptotic Bcl-2 family member, might be involved in dioscorealide B-induced apoptosis. Bid is a specific proximal substrate of caspase-8 in the Fas apoptotic signaling pathway. While full-length BID is localized in cytosol, truncated BID (tBID) translocates to mitochondria and, therefore, transduces apoptotic signals from the cytoplasmic membrane to mitochondria. tBID induces first the clustering of mitochondria around the nuclei and release of cytochrome c independent of caspase activity, and then the loss of mitochondrial membrane potential, cell shrinkage, and nuclear condensation in a caspasedependent fashion [26] .
In conclusion, for the first time, the mechanisms of dioscorealide B against breast cancer were elucidated. The results of the present study indicated that dioscorealide B treatment decreased the expression of antiapoptotic protein Bcl-2 and increased the expression of proapoptotic proteins Bax and Bak, which leads to the activation of caspase-9 and -7, respectively. These studies thus provide the molecular basis for the further development of dioscorealide B as a novel chemotherapeutic agent for breast cancer treatment. 
Isolation of dioscorealide B:
Dioscorealide B was isolated following the method previously described and agreed in all respects as regards reported chromatographic and spectral data [8] .
Cell culture conditions: MCF-7 human breast cancer cell line was kindly provided by Dr P. Twentyman and Dr P. Rabbitts of MRC Clinical Oncology & Radiotherapeutics Unit, Cambridge, UK. Cells were cultured in monolayers in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 100 µg/mL penicillin, and 100 µg/mL streptomycin and maintained at 37°C in a humidified atmosphere of 5% CO 2 .
SRB assay:
The cytotoxicity assay was carried out using the sulforhodamine B (SRB) assay [8, 27] . Briefly, 3,000 of MCF-7 cells were plated per well in 96-well culture plates kept in an incubator at 37°C. After overnight incubation, the cells were treated without or with dioscorealide B 0.03, 0.15, 0.3, 1.5, 3, 15, 30, 150 µM, with 6 replications. The cells were incubated for 72 h and then the medium was removed and washed. The survival percentage was measured colorimetrically using the SRB assay, and IC 50 values were calculated by means of the Prism program. Cells incubated with regular cell culture media with 0.2% DMSO were used as a negative control and vinblastine sulfate as a positive control.
Annexin V-FITC assay: Induction of apoptosis by dioscorealide B treatment was measured by an Annexin V-FITC apoptosis detection kit, following the manufacture's instructions. Briefly, MCF-7 cells (1×10 6 cells) were seeded in 12-well plates and treated with dioscorealide B at 3, 6 and 12 µM. After 24 h, cells were collected, washed with cold PBS twice, gently resuspended in 100 µl of staining solution (containing annexin V, fluorescein and propidium iodide in a HEPES buffer). After incubation at room temperature for 15 min, cells were analyzed by flow cytometry. Annexin V binds to those cells that express phosphotidylserine on the outer layer of the cell, and propidium iodide stains the cellular DNA of those cells with a compromised cell membrane. This allows for the discrimination of live cells (unstained with either fluorochrome) from apoptotic cells (stained only with annexin V) and necrotic cells (stained with both annexin V and propidium iodide).
Caspase-7, -8 and -9 activity assay:
The Caspase-Glo ® -3/7, -8 and -9 assays were used to measure caspase-3/7, caspase-8 and caspase-9 activity. Briefly, 10 4 cells were cultured in 96-well plates and treated with dioscorealide B (3, 6 or 12 µM). After the incubation period, caspase-Glo® reagent was added to each well according to the manufacturer's instructions. Plates were mixed on a plate shaker for 30 secs and incubated at room temperature for 1 h. Luminescence was measured using a luminometer. The assay was performed in triplicate.
Western blotting: After treatment, cells were washed with ice-cold PBS and lysed with SDS lysis buffer. The protein concentration of the supernatant was determined by the Bradford method. The lysates were subjected to electrophoresis on a 12% SDS-polyacrylamide gel and then transferred to a PVDF membrane. After the membrane was blocked in Tris-buffer saline (TBST) containing 0.05% Tween 20 and 5% nonfat powdered milk, the membranes were incubated with primary antibodies specific for Bax, Bak, Bcl-2 and caspase-7. After washing 3 times with TBST for 10 min each, the membrane was incubated with horseradish peroxidaselabeled secondary antibody for 1 h. The membranes were washed again, and detection was performed using the enhanced chemiluminescence blotting detection system (Amersham, USA).
Statistics: Data were expressed as means ± SEM. Statistical comparisons of the results were made using analysis of variance (ANOVA) and a P value less than 0.05 was considered significant.
